Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In these short interviews, Anna Kordala and Jane Millar talk about the research they do at the Department of Paediatrics.

Anna Kordala; DPhil student, Wood Group

Anna KordalaCan you tell us more about your role?

I am a third year DPhil student in Professor Matthew Wood group, working on epigenetic regulation of SMN protein, insufficiency of which leads to a paediatric neuromuscular disorder called spinal muscular atrophy. We are a part of MD UK Oxford Neuromuscular Centre, which aims at accelerating drug development. Before starting my DPhil, I worked as a Research Assistant in the very same group, and I highly recommend it to anyone before their DPhil, if you are not sure what you want to specialize in. In parallel, I am a science communicator in SMA Foundation in Poland.


What is the most meaningful aspect of your work?

Bridging the communication gap between scientists and patient communities.


Can you tell us about something you’ve done, contributed to that you’re most proud of?

Professionally speaking, I am most proud of being involved in adding spinal muscular atrophy to the National New-born Screening Programme in Poland. In SMA, the timing is key. Treating new-borns before onset of symptoms results in a close to normal development of these children, who would otherwise be severally disabled.


What changes would you most like to see in the Medical Sciences in the next 100 years?

I would like the below t-shirt slogan to become true: The future is inclusive.



Jane Millar; DPhil graduate, HIV Group

Jane MillarCan you tell us more about your role?

I have very recently finished my DPhil on paediatric HIV and am now back training to be a paediatric infectious disease specialist, working for the NHS. 

I left New Zealand in 2015 and set off to work as a doctor in South Africa. I took up the offer to do a DPhil, because it provided the opportunity to slow down, and research how to solve a significant problem in child health, rather than just treat it when it presents to a hospital. Most of what I learnt about HIV is applicable to most other infectious diseases, which more obviously after the Covid-19 pandemic, is a crucial issue in medical sciences.


What is the most meaningful aspect of your work?

It is such a privilege having families and patients share their stories with me.


Can you tell us about something you’ve done, contributed to that you’re most proud of?

I helped expand and coordinate the Ucwaningo Lwabantwana study in KwaZulu-Natal South Africa, which explored testing and treating HIV-infected infants in the first hours of life. This was a really difficult study, because we worked with impoverish, rural families who were struggling in a fragmented health system, so adherence was far from ideal. But the study highlighted the unmet needs of these families and will hopefully encourage better paediatric treatment modalities.


What changes would you most like to see in the Medical Sciences in the next 100 years?

More funding for research in preventable diseases, particularly where there is an associated socio-economic gradient, as well as more emphasis on supporting mental health.

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.